148 related articles for article (PubMed ID: 31068367)
61. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
[TBL] [Abstract][Full Text] [Related]
62. Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Poller B; Iusuf D; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Drug Metab Dispos; 2011 May; 39(5):729-35. PubMed ID: 21282407
[TBL] [Abstract][Full Text] [Related]
63. Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1).
Schmitt SM; Stefan K; Wiese M
J Med Chem; 2016 Apr; 59(7):3018-33. PubMed ID: 26943020
[TBL] [Abstract][Full Text] [Related]
64. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
[TBL] [Abstract][Full Text] [Related]
65. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.
Chen Z; Shi T; Zhang L; Zhu P; Deng M; Huang C; Hu T; Jiang L; Li J
Cancer Lett; 2016 Jan; 370(1):153-64. PubMed ID: 26499806
[TBL] [Abstract][Full Text] [Related]
66. The Effects of Drug Metabolizing Enzyme Inhibitors on Hepatic Efflux and Uptake Transporters.
Cheong J; Halladay JS; Plise E; Sodhi JK; Salphati L
Drug Metab Lett; 2017; 11(2):111-118. PubMed ID: 29032766
[TBL] [Abstract][Full Text] [Related]
67. 3-Methyladenine can depress drug efflux transporters via blocking the PI3K-AKT-mTOR pathway thus sensitizing MDR cancer to chemotherapy.
Zou Z; Zhang J; Zhang H; Liu H; Li Z; Cheng D; Chen J; Liu L; Ni M; Zhang Y; Yao J; Zhou J; Fu J; Liang Y
J Drug Target; 2014 Nov; 22(9):839-48. PubMed ID: 25019701
[TBL] [Abstract][Full Text] [Related]
68. cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma.
Berberich A; Schmitt LM; Pusch S; Hielscher T; Rübmann P; Hucke N; Latzer P; Heßling B; Lemke D; Kessler T; Platten M; Wick W
J Neurooncol; 2020 Jan; 146(1):9-23. PubMed ID: 31776900
[TBL] [Abstract][Full Text] [Related]
69. Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters.
Sorf A; Novotna E; Hofman J; Morell A; Staud F; Wsol V; Ceckova M
Biochem Pharmacol; 2019 May; 163():290-298. PubMed ID: 30826329
[TBL] [Abstract][Full Text] [Related]
70. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
71. In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes.
Nakagawa T; Fowler S; Takanashi K; Youdim K; Yamauchi T; Kawashima K; Sato-Nakai M; Yu L; Ishigai M
Xenobiotica; 2018 Jun; 48(6):546-554. PubMed ID: 28657423
[TBL] [Abstract][Full Text] [Related]
72. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
Wang J; Gan C; Sparidans RW; Wagenaar E; van Hoppe S; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Mar; 129():414-423. PubMed ID: 29155017
[TBL] [Abstract][Full Text] [Related]
73. Zafirlukast antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.
Sun YL; Kathawala RJ; Singh S; Zheng K; Talele TT; Jiang WQ; Chen ZS
Anticancer Drugs; 2012 Sep; 23(8):865-73. PubMed ID: 22614107
[TBL] [Abstract][Full Text] [Related]
74. Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells.
Wu ZX; Teng QX; Cai CY; Wang JQ; Lei ZN; Yang Y; Fan YF; Zhang JY; Li J; Chen ZS
Biochem Pharmacol; 2019 Aug; 166():120-127. PubMed ID: 31078601
[TBL] [Abstract][Full Text] [Related]
75. SIS3, a specific inhibitor of Smad3 reverses ABCB1- and ABCG2-mediated multidrug resistance in cancer cell lines.
Wu CP; Murakami M; Hsiao SH; Liu TC; Yeh N; Li YQ; Hung TH; Wu YS; Ambudkar SV
Cancer Lett; 2018 Oct; 433():259-272. PubMed ID: 30026175
[TBL] [Abstract][Full Text] [Related]
76. Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2.
Silbermann K; Shah CP; Sahu NU; Juvale K; Stefan SM; Kharkar PS; Wiese M
Eur J Med Chem; 2019 Feb; 164():193-213. PubMed ID: 30594677
[TBL] [Abstract][Full Text] [Related]
77. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
[TBL] [Abstract][Full Text] [Related]
78. Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactions.
Schiller H; Huth F; Schuhler C; Drollmann A; Kaul M; Woessner R; Shah B; Weis W; End P
Eur J Pharm Sci; 2022 May; 172():106155. PubMed ID: 35247543
[TBL] [Abstract][Full Text] [Related]
79. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges.
Shukla S; Wu CP; Ambudkar SV
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):205-23. PubMed ID: 18248313
[TBL] [Abstract][Full Text] [Related]
80. Collateral sensitivity: ABCG2-overexpressing cells are more vulnerable to oxidative stress.
Krzyżanowski D; Bartosz G; Grzelak A
Free Radic Biol Med; 2014 Nov; 76():47-52. PubMed ID: 25064323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
